Status
Conditions
Treatments
About
This prospective, multi center cohort trial aims to evaluate the efficacy and safety of hysteropexy using Splentis via the vaginal route in primary uterine prolapse
Full description
Women who undergo hysteropexy with Splentis via the vaginal route for primary uterine prolapse will be evaluated regarding efficacy and safety in a long term follow-up of 60 months. The primary endpoint is composed of anatomical, subjective and re-treatment components, whereas several secondary endpoints focusing on functional outcome including overactive bladder symptoms, urinary incontinence, quality of life and sexual life will be considered. Furthermore, a detailed report about adverse events will be included.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
140 participants in 1 patient group
Loading...
Central trial contact
Philipp Schelhorn; Lorena López, Ph.D, Bioeng
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal